Eli Lilly's new weight-loss drug wows Wall Street — ride the breakout higher
Thesis
Eli Lilly is already a dominant player in the obesity drug market, but these strong trial results confirm their pipeline has staying power against competitors. Analysts at major banks have pointed out that the company's portfolio is well-diversified and not reliant on just one hit product. When a company beating expectations this significantly, institutional money usually flows in over the following days and weeks as portfolios rebalance, driving the price even higher.
Strategy approach
Build a momentum strategy for LLY on the daily timeframe. Enter long when the stock closes above its 5-day high, with an entry condition requiring the daily RSI(14) to be above 60. Exit the position if the stock closes below its 10-day moving average, or use a 5% trailing stop, whichever triggers first. Cap the holding period at 15 trading days.